Menarini, chased by 3 Big Pharmas, records win in breast cancer phase 3, plots path to FDA

Menarini and Radius Health have gained a lead over AstraZeneca, Roche and Sanofi in the race to bring a new class of oral breast cancer drugs to market, posting phase 3 data and outlining plans to seek approvals on both sides of the Atlantic next year.